GlassScriptPhysician profile
Beth C Gardner
NPI 1457334369
$121,772.03
in general payments reported to CMS, 2019-2025
34 companies · $33K in 2025
The $33K reported for 2025 was more than what 96% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $7,081 · 2021: $15K · 2022: $18K · 2023: $19K · 2024: $16K · 2025: $33K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $46K · Food and Beverage: $11K · Debt Forgiveness: $9,728 · Travel and Lodging: $1,397 · Education: $14.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,762.50 |
| Food and Beverage | $11,104.77 |
| Debt Forgiveness | $9,727.75 |
| Travel and Lodging | $1,396.89 |
| Education | $14.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $39,614.53 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $23,421.76 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $19,970.36 | 2020-2023 | |
| Allergan, INC. | $13,489.98 | 2019-2020 | |
| Olympus America INC. | $9,727.75 | 2025 | Gastrointestinal Videoscope, Evis Exera III Colonovideoscope |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $4,812.22 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Qol Medical, LLC | $2,477.32 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $1,452.78 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $872.24 | 2019-2025 | Epclusa |
| Ardelyx, INC. | $837.81 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $705.57 | 2019-2025 | Stelara, Tremfya, Simponi Aria |
| Ironwood Pharmaceuticals, INC | $653.82 | 2020-2024 | Linzess |
| Celgene Corporation | $641.10 | 2021-2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $423.78 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $279.85 | 2019-2024 | Dificid |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $278.10 | 2020-2024 | Gimoti |
| Pfizer INC. | $255.97 | 2020-2025 | |
| Lilly USA, LLC | $247.43 | 2023-2025 | Omvoh |
| Madrigal Pharmaceuticals | $210.39 | 2024-2025 | Rezdiffra, Resmetirom |
| Ucb, INC. | $206.75 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $202.68 | 2022-2025 | Dupixent |
| Braintree Laboratories, INC. | $184.63 | 2019-2024 | Suflave, Sutab |
| Vivus LLC | $170.16 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $159.34 | 2019-2022 | |
| Genzyme Corporation | $145.21 | 2022-2025 | |
| Daiichi Sankyo INC. | $80.88 | 2019-2022 | |
| Celltrion USA INC. | $65.72 | 2024-2025 | Vegzelma, Zymfentra |
| Novo Nordisk INC | $47.74 | 2025 | Wegovy |
| Alfasigma USA, INC. | $39.66 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $38.80 | 2024 | Bylvay |
| Meridian Bioscience INC. | $21.33 | 2024 | |
| Shionogi INC | $12.75 | 2019 | |
| Redhill Biopharma INC. | $12.62 | 2020 | |
| Boston Scientific Corporation | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Gardner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.